PubMed · 2001 · 66 citations · 10 references
MedicinePharmacologyPharmacotherapyCancer PharmacologyCervical DiseaseClinical PharmacologyCervical CancerCervical Intraepithelial NeoplasiaCervical LesionsRetinoic Acid SignalingSquamous Cell CarcinomaCervical Intraepithelial Neoplasia 2Cervical Intraepithelial Neoplasia 3Cervical Intraepithelial Neoplasia TreatmentInterim AnalysisRandomized Clinical Trials
PURPOSE: Previous trials of topical trans-retinoic acid treatment of cervical intraepithelial neoplasia (CIN) grades 2 and 3 led to a statistically significant regression of CIN 2, but not CIN 3. We tested N-(4-hydroxyphenyl)retinamide (4-HPR), a promising oral retinoid that has been shown to induce apoptosis through nonretinoic receptor acid-mediated pathways, for its toxicity and efficacy against CIN 2/3. EXPERIMENTAL DESIGN: In a blinded randomized trial, 4-HPR at 200 mg/day for 6 months (with a 3-day/month drug holiday) was compared with placebo in patients with biopsy-proven CIN-2/3 [high-grade squamous intraepithelial lesions (HGSILs)]. Patients were treated with placebo or 4-HPR for 6 months, biopsied, and then followed for an additional 6 months. At the 12-month end point, they underwent either loop excision if a histological lesion was present or a biopsy from the original area of the lesion if no lesion was present. RESULTS: An interim analysis of blinded data showed a significantly worse prognosis at 12 months for one group. When the code was broken because of the poorer outcomes, we discovered that the 4-HPR treatment arm was performing more poorly than was the placebo at 6 and 12 months (25 versus 44% response rates at 6 months; 14 versus 50% at 12 months). Toxicity was not significant in either arm. CONCLUSIONS: 4-HPR at 200 mg/day with a 3-day/month drug holiday is not active compared with placebo in the treatment of HGSIL. Because 4-HPR is active in the laboratory, the lack of effect in our trial may indicate that higher doses are needed in patients to achieve comparable results.
10
Retinoids as preventive and therapeutic anticancer agents (Part I).
Lippman Sm, Kessler Jf, Meyskens Fl · PubMed · 1987 · 361 citations
Medicine, Oncology, Pharmacology +14